PDL BioPharma CEO Presents at Goldman Sachs Healthcare Conference ... Seeking Alpha In looking for second generation products rituxan they basically divided the franchisee in half, half were targeted towards blood-borne cancers of rituximab being in that case and the others are targeted towards the autoimmune conditions rheumatoid ... |
